Skip to content

NYSE · CIK 0001006837

VATE INNOVATE Corp.

Insider trading from SEC Form 4. Last filing 25 d ago. Close $7.22 on Oct 9, 2026, +81% from the 52-week low and -64% from the high.

Last 90 days

Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
6
with a Form 4 at this company

Price and insider trades, last year

VATEOct 9, 2026 · close 7.22

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

Open-market buys and sells at INNOVATE Corp., scored.

ScoreInsiderValueHoldingsPrice contextFiled
43ModeratePaul Voigt
Interim CEO
buy
$100k
25,000 shares
--

Transactions

The last 25 rows filed, every code.

DateInsiderTransactionSharesPriceValueHoldings afterFiled
Sep 15, 2026Paul Voigt
Interim CEO
AGrant or award
Stock Opion (right to buy)derivative
+100,000$0.00$0100,00025 d ago
Mar 13, 2026Michael J. Sena
Chief Financial Officer
FTax withholding
Common Stock
-1,784$4.35$7,760122,109Mar 16, 2026
Mar 14, 2026Michael J. Sena
Chief Financial Officer
FTax withholding
Common Stock
-4,920$4.22$21k117,189Mar 16, 2026
Mar 15, 2026Michael J. Sena
Chief Financial Officer
FTax withholding
Common Stock
-1,207$4.22$5,094115,982Mar 16, 2026
Sep 15, 2025Paul Voigt
Interim CEO
AGrant or award
Stock option (Right To Buy)derivative
+100,000$0.00$0100,000Sep 17, 2025
Aug 6, 2025Paul Voigt
Interim CEO
AGrant or award
Common Stock
+176,056$5.68$1000k625,890Aug 7, 2025
Aug 4, 2025Avram A Glazer
director, owner
SOpen-market sale
7.5% Convertible Senior Notes due 2026derivativeindirect: Lancer Capital
----Aug 6, 2025
Aug 4, 2025Avram A Glazer
director, owner
POpen-market purchase
9.5% Convertible Senior Notes due 2027derivativeindirect: Lancer Capital
----Aug 6, 2025
Jun 12, 2025Warren H Gfeller
director
AGrant or award
Common Stock
+16,363$0.00$067,703Jun 16, 2025
Jun 12, 2025Avram A Glazer
director, owner
AGrant or award
Common Stock
+16,363$0.00$053,984Jun 16, 2025
Jun 12, 2025Brian Steven Goldstein
director
AGrant or award
Common Stock
+16,363$0.00$048,983Jun 16, 2025
Jun 12, 2025Amy Marie Wilkinson
director
AGrant or award
Common Stock
+16,363$0.00$046,904Jun 16, 2025
Mar 14, 2025Michael J. Sena
Chief Financial Officer
FTax withholding
Common Stock
-4,302$7.66$33k124,946Mar 17, 2025
Mar 15, 2025Michael J. Sena
Chief Financial Officer
FTax withholding
Common Stock
-1,053$7.81$8,224123,893Mar 17, 2025
Mar 11, 2025Michael J. Sena
Chief Financial Officer
FTax withholding
Common Stock
-862$7.23$6,232116,302Mar 13, 2025
Mar 13, 2025Michael J. Sena
Chief Financial Officer
AGrant or award
Common Stock
+12,946$0.00$0129,248Mar 13, 2025
Dec 16, 2024Avram A Glazer
director, owner
GGift
Common Stock
-2,097,902$0.00$02,135,523Dec 18, 2024
Dec 16, 2024Avram A Glazer
director, owner
GGift
Common Stock
-2,097,902$0.00$037,621Dec 18, 2024
Dec 16, 2024Avram A Glazer
director, owner
GGift
Common Stockindirect: LHG Irrevocable Exempt Trust
+2,097,902$0.00$02,097,902Dec 18, 2024
Dec 16, 2024Avram A Glazer
director, owner
GGift
Common Stockindirect: KAG Irrevocable Exempt Trust
+2,097,902$0.00$02,097,902Dec 18, 2024
Nov 19, 2024Paul Voigt
Interim CEO
POpen-market purchase
Common Stockindirect: Paul K Voigt Rev Trust
+25,000$3.98$100k25,000Nov 21, 2024
Oct 29, 2024Paul Voigt
Interim CEO
AGrant or award
Common Stock
+95,322$0.00$0306,977Oct 30, 2024
Oct 29, 2024Paul Voigt
Interim CEO
AGrant or award
Common Stock
+142,857$0.00$0449,834Oct 30, 2024
Oct 29, 2024Paul Voigt
Interim CEO
AGrant or award
Stock option (Right To Buy)derivative
+100,000$0.00$0100,000Oct 30, 2024
Oct 29, 2024Paul Voigt
Interim CEO
AGrant or award
Stock option (Right To Buy)derivative
+100,000$0.00$0100,000Oct 30, 2024

Insiders

Everyone who has filed a Form 4 here.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.